Nivolumab in previously untreated melanoma without BRAF mutation

Area of Science:

• Oncology
• Immunotherapy
• Melanoma Research

Background:

• Metastatic melanoma treatment options were limited, especially for patients refractory to ipilimumab.
• Nivolumab demonstrated efficacy in ipilimumab-refractory cases, but its use in treatment-naive patients required further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of nivolumab compared to dacarbazine in previously untreated patients with metastatic melanoma.
• To determine if nivolumab offers survival benefits in advanced melanoma without BRAF mutations.

Main Methods:

• A phase 3, randomized controlled trial (CheckMate 066) involving 418 treatment-naive patients.
• Patients received either nivolumab (3 mg/kg every 2 weeks) or dacarbazine (1000 mg/m² every 3 weeks).
• Primary endpoint was overall survival; secondary endpoints included progression-free survival and objective response rate.

Main Results:

• Nivolumab significantly improved 1-year overall survival (72.9% vs. 42.1%) and median progression-free survival (5.1 vs. 2.2 months).
• Objective response rate was higher with nivolumab (40.0% vs. 13.9%).
• Survival benefits were consistent across subgroups, including PD-L1 status; Grade 3/4 adverse events were lower with nivolumab (11.7% vs. 17.6%).

Conclusions:

• Nivolumab demonstrated significant improvements in overall survival and progression-free survival compared to dacarbazine.
• Nivolumab represents a new standard of care for previously untreated metastatic melanoma patients without BRAF mutations.